Clinical Trial Update: An Expanded Safety Study of Dapivirine Gel 4789 in Africa [Phase 1, Phase 2]

View source ↗

Summary

An expanded safety study of the dapivirine vaginal gel (4789) in Africa has completed Phase 1/2 trials to assess safety for HIV prevention.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• Dapivirine Gel 4789 (dapivirine)

Snippet

Sponsor: International Partnership for Microbicides, Inc. | Conditions: HIV Infections, Acquired Immunodeficiency Syndrome | Phase 1, Phase 2 | Status: COMPLETED